| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.TP.0000123082.31092.53 |
| P698 | PubMed publication ID | 15239621 |
| P2093 | author name string | Mark D Stegall | |
| Patrick G Dean | |||
| Michael B Ishitani | |||
| Scott L Nyberg | |||
| Walter K Kremers | |||
| Timothy S Larson | |||
| Mikel Prieto | |||
| William J Lund | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sirolimus | Q32089 |
| kidney transplantation | Q740909 | ||
| wound healing | Q1509074 | ||
| P304 | page(s) | 1555-1561 | |
| P577 | publication date | 2004-05-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus | |
| P478 | volume | 77 |
| Q92120935 | A 3-month, Multicenter, Randomized, Open-label Study to Evaluate the Impact on Wound Healing of the Early (vs Delayed) Introduction of Everolimus in De Novo Kidney Transplant Recipients, With a Follow-up Evaluation at 12 Months After Transplant (NEV |
| Q39024541 | A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation |
| Q33602527 | A comprehensive review of immunosuppression used for liver transplantation |
| Q38041260 | A drug safety evaluation of everolimus in kidney transplantation |
| Q37606449 | A major burn injury in a liver transplant patient |
| Q37386368 | AGEs Induced Autophagy Impairs Cutaneous Wound Healing via Stimulating Macrophage Polarization to M1 in Diabetes |
| Q61445929 | Abdominal wall complications following renal transplantation in adult recipients - factors associated with interventional management in one unit |
| Q38727798 | Addressing inherited predisposition for breast cancer in transplant recipients |
| Q38068519 | Adverse events associated with mTOR inhibitors |
| Q51749477 | Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study. |
| Q38038696 | An evaluation of sirolimus in renal transplantation |
| Q97886301 | Bafilomycin A1 Accelerates Chronic Refractory Wound Healing in db/db Mice |
| Q33364817 | Benefit-risk assessment of sirolimus in renal transplantation |
| Q38817264 | Biomaterial-Based Approaches to Address Vein Graft and Hemodialysis Access Failures |
| Q45002395 | Calcineurin inhibitor avoidance versus steroid avoidance following kidney transplantation: Postoperative complications |
| Q38668601 | Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients. |
| Q43823533 | Calcineurin inhibitor-free immunosuppression in dual kidney transplantation from elderly donors |
| Q79438918 | Changes in abdominal wounds following treatment with sirolimus and steroids in a rat model |
| Q30419381 | Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin |
| Q36797796 | Comparison of Minimal Skin Incision Technique in Living Kidney Transplantation and Conventional Kidney Transplantation |
| Q46936585 | Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus |
| Q90669418 | Complications, length of stay, and cost of cholecystectomy in kidney transplant recipients |
| Q37204903 | Composite tissue allotransplantation of the face: Decision analysis model. |
| Q26992343 | Corticosteroid and calcineurin inhibitor sparing regimens in kidney transplantation |
| Q27694591 | Current status of immunosuppression in liver transplantation |
| Q37987565 | Current status of immunosuppressive agents for solid organ transplantation in children |
| Q39269082 | Cutaneous Toxicities From Transplantation-Related Medications |
| Q36899362 | Defects in skin gamma delta T cell function contribute to delayed wound repair in rapamycin-treated mice |
| Q96130010 | Determinants of Successful Use of Sirolimus in Renal Transplant Patients |
| Q26823281 | Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials |
| Q50985003 | Does ultrasonic energy for surgical dissection reduce the incidence of renal transplant lymphocele? |
| Q80381341 | Effect of rapamycin on wound healing: an experimental study |
| Q37987997 | Effects of immunosuppressive therapy on wound healing |
| Q36289418 | Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing |
| Q36758582 | Emerging drugs in lung transplantation |
| Q64073109 | Evaluation of the use of tacrolimus ointment for the prevention of hypertrophic scars in experimental model |
| Q38646743 | Everolimus immunosuppression in kidney transplantation: What is the optimal strategy? |
| Q41384256 | Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus. |
| Q57119713 | Everolimus-induced loss of wound strength can be prevented by a short postoperative delay in its administration |
| Q37355472 | Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients |
| Q46480351 | Favorable results of concomitant tacrolimus and sirolimus therapy in Taiwanese renal transplant recipients at 12 months |
| Q40895259 | Growth hormone abolishes the negative effects of everolimus on intestinal wound healing |
| Q83937496 | Healing of surgical incision in kidney transplantation: a single transplant center's experience |
| Q36433573 | Immunosuppression for heart transplantation: where are we now? |
| Q39016575 | Immunosuppression in pediatric liver transplant recipients: Unique aspects |
| Q33799731 | Immunosuppressive cyclosporin A activates AKT in keratinocytes through PTEN suppression: implications in skin carcinogenesis |
| Q38131036 | Impact of mTOR-I on fertility and pregnancy: state of the art and review of the literature. |
| Q38187974 | Impaired lower extremity wound healing secondary to sirolimus after kidney transplantation |
| Q31107136 | Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA study group |
| Q96346903 | Incisional Hernia After Orthotopic Liver Transplantation: A Systematic Review and Meta-analysis |
| Q45928212 | Increased mycophenolic acid exposure in stable kidney transplant recipients on tacrolimus as compared with those on sirolimus: implications for pharmacokinetics. |
| Q54597078 | Indications and effectiveness of the mammalian target of rapamycin in liver transplantation. |
| Q42065624 | Individualized immunosuppression in transplant patients: potential role of pharmacogenetics |
| Q37822152 | Individualizing early use of sirolimus in renal transplantation |
| Q51337905 | Is polypropylene mesh safe and effective for repairing infected incisional hernia in renal transplant recipients? |
| Q91097645 | Laparoscopic Repair of Boundary Incisional Hernia in a Kidney Transplant Patient: A Safe Tacks-Fibrin Glue Combined Mesh Fixation Technique |
| Q26785848 | Lymphatic disorders after renal transplantation: new insights for an old complication |
| Q83937504 | Lymphocele after renal transplantation: the influence of the immunosuppressive therapy |
| Q50610813 | Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing. |
| Q48243854 | Managing risk of surgical procedures in pediatric transplant recipients taking mTOR inhibitors: What is the optimal strategy? |
| Q39045625 | Mesenchymal stromal cells with enhanced therapeutic properties |
| Q40268724 | Minimally invasive kidney transplantation: the first experience |
| Q36724093 | Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines |
| Q36575992 | Mycophenolate mofetil and sirolimus combination in renal transplantation |
| Q46703423 | Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen |
| Q84289068 | New immunosuppressive therapies and surgical complications after renal transplantation |
| Q45166011 | No-load sirolimus with tacrolimus and steroids is safe and effective in renal transplantation |
| Q58766893 | Optimal surgical management in kidney and pancreas transplantation to minimise wound complications: A systematic review and meta-analysis |
| Q41149121 | Our First Experience With Negative Pressure Incision Management System Implemented on the Clean Surgical Incision in the Renal Transplantation Recipient: A Case Report |
| Q88598863 | Outcomes Following Colorectal Resection in Kidney Transplant Recipients |
| Q42502255 | Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation |
| Q42555714 | Overview of immunosuppression in liver transplantation |
| Q34625055 | Peripheral artery disease and chronic kidney disease: clinical synergy to improve outcomes |
| Q36379888 | Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients |
| Q44809084 | Post-kidney transplant surgical complications under new immunosuppressive regimens |
| Q45951672 | Post-renal transplant surgical complications with newer immunosuppressive drugs: mycophenolate mofetil vs. m-TOR inhibitors. |
| Q42175616 | Post-transplantation nephroptosis causing recurrent episodes of acute renal failure and hypertension secondary to intermittent vascular torsion of intraperitoneal renal allograft |
| Q54335179 | Preliminary report of major surgery in liver transplant recipients receiving m-TOR inhibitors without therapeutic discontinuation. |
| Q79438972 | Proteinuria after conversion to sirolimus in renal transplant recipients |
| Q44570490 | Rabbit antithymocyte globulin: a postoperative risk factor for sirolimus-treated renal transplant patients? |
| Q46014886 | Recipient and donor risk factors for surgical complications following kidney transplantation. |
| Q33871855 | Relationship between Post-kidney Transplantation Antithymocyte Globulin Therapy and Wound Healing Complications |
| Q89478971 | Renal Transplantation Is Associated with Increased Complications Following Spinal Fusion Operations: Analysis of a National Database |
| Q64895025 | Repair of gastrocutaneous fistula utilizing thickened fluids: application of Poiseuille's Law to fistula healing. |
| Q38084745 | Right diaphragmatic hernia after liver transplant in pediatrics: a case report and review of the literature. |
| Q62671523 | Risk Factors for Wound Healing Complications in Sirolimus-Treated Renal Transplant Recipients |
| Q36889289 | Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients |
| Q47631182 | Risk factors of severe incisional hernia after renal transplantation: a retrospective multicentric case-control study on 225 patients |
| Q40145626 | Sickle Cell Anemia and Comorbid Leg Ulcer Treated With Curative Peripheral Blood Stem Cell Transplantation |
| Q43224700 | Side effects of proliferation signal inhibitors and their management |
| Q42943653 | Similar early complication rate in simultaneous pancreas and kidney recipients on tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus immunosuppressive regimens. |
| Q56908156 | Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6-Month Course of Steroids |
| Q46787464 | Sirolimus and intraoperative hyperthermic peritoneal chemoperfusion with mitomycin-C do not impair healing of bowel anastomoses |
| Q80035894 | Sirolimus impairs wound healing |
| Q33397668 | Sirolimus in pediatric renal transplantation |
| Q85666929 | Sirolimus vs cyclosporine after induction with basiliximab does not promote regulatory T cell expansion in de novo kidney transplantation: Results from a single-center randomized trial |
| Q46903645 | Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism |
| Q47862281 | Successful management of eviscerated renal allograft with preservation of function |
| Q88170110 | Surgical approach, cost, and complications of appendectomy in kidney transplant recipients |
| Q37854845 | Surgical wound complications after heart transplantation |
| Q36241659 | Systematic review of the negative pressure wound therapy in kidney transplant recipients |
| Q26823023 | Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors |
| Q35006318 | Tacrolimus does not affect early wound healing in a rodent model of bowel anastomoses and abdominal wall closure |
| Q24246340 | Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients |
| Q42910514 | Targeting risk factors for impaired wound healing and wound complications after kidney transplantation |
| Q46843926 | The approach by midline incision for extraperitoneal kidney transplantation. |
| Q38003006 | Torsion of intraperitoneal kidney transplant. |
| Q36750090 | Use of sirolimus in solid organ transplantation |
| Q51595119 | Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus. |
| Q46001916 | Wound complications after kidney transplantation in nondiabetic patients. |
| Q36652072 | Wound complications following kidney and liver transplantation |
| Q57793035 | Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials |
| Q45992631 | Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. |
| Q81287527 | [Pathogenesis of chronic wounds] |
| Q38209973 | mTOR inhibitors and renal allograft: Yin and Yang. |
| Q38962103 | mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions |
| Q38112331 | mTOR inhibitors in pediatric kidney transplantation |
Search more.